BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation therapeutic. BioDlink provided end-to-end development and manufacturing support, showcasing its industry-leading ADC capabilities. Approval marks a key milestone in the...
Gates Foundation Will Double Spending Over Next 20 Years to Accelerate Progress on Saving and Improving Lives
On foundation's 25th anniversary, Bill Gates outlines ambitious goals, inspiration for donating most of his resources and new timeline to spend-down by 2045 SEATTLE, May 8, 2025 /PRNewswire/ -- On the occasion of its 25th year, the Gates Foundation today made a new commitment to accelerate its mission to help all people live...
Colorcon and ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical and Nutraceutical Industries
HARLEYSVILLE, Pa. and MUMBAI, India, May 8, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the healthcare industry, today announced an exclusive partnership with ASHA Cellulose, a leading provider of organo-soluble Ethyl cellulose polymers widely used in...
Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers
HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide....
QDX Congratulates Co-Founder and Head of Research A/Prof. Giuseppe Barca on Receiving the 2025 Dirac Medal
SINGAPORE, May 8, 2025 /PRNewswire/ -- QDX proudly congratulates its Co-Founder and Head of Research, A/Prof. Giuseppe Barca, on being awarded the 2025 Dirac Medal, the highest international honour for early-career researchers in theoretical and computational chemistry. Presented by the World Association of Theoretical and Computational Chemists (WATOC), the Dirac Medal recognises scientists under 40 whose research has...
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
Penetrium™ Achieves Historic Breakthrough Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy Presented at AACR 2025, Chicago CHICAGO, May 8, 2025 /PRNewswire/ -- Hyundai Bioscience presented the results of its Penetrium™ combination preclinical studies at the 2025 American Association for Cancer...
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SINGAPORE, May 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous HBV-specific TCR-T cell therapy, in patients with advanced HBV-related hepatocellular carcinoma (HCC). These data were presented at the...
‘No Child Left Behind’ as Singapore Turns 60: New Digital Early Intervention Platform PEIVE Launches for Inclusive Progress
SINGAPORE, May 8, 2025 /PRNewswire/ -- As Singapore celebrates 60 years of independence (SG60), a new ground-up initiative is reminding the nation that true progress is measured by how we care for our most vulnerable. Today, local therapists and educators announced the launch of PEIVE (Paving Early Interventions with Vision and Empathy) , a digital Early Intervention (EI)...
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179’s Role in Advancing Higher HBsAg Loss
End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants , strengthening the case for a novel enrichment strategy, utilizing BRII-179 to identify and prime patients for improved...
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and...
